Search

Your search keyword '"Decaens, T"' showing total 305 results

Search Constraints

Start Over You searched for: Author "Decaens, T" Remove constraint Author: "Decaens, T"
305 results on '"Decaens, T"'

Search Results

2. PD1 and TIM3 Expression is Associated with Very Early Hepatocellular Carcinoma Recurrence After Percutaneous Thermal Ablation

4. AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool

8. Livret d’aide à l’éducation thérapeutique du patient recevant des chimiothérapies anticancéreuses intraveineuses et orales en oncologie digestive

10. 950P Outcomes by baseline tumour burden in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)

13. R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation

14. Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

17. Abstract No. 117 A phase 3, double-blind, randomized study of nivolumab and Ipilimumab), nivolumab monotherapy, or placebo plus transarterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma

21. Liver-targeted disruption of Apc in mice activates [beta]-catenin signaling and leads to hepatocellular carcinomas

27. Meeting Abstract: 745P

28. Biofunctool (R) : a new framework to assess the impact of land management on soil quality. Part A : concept and validation of the set of indicators

33. Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients

37. Abstract No. 526 CheckMate-9DX: phase 3, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

38. CLINICAL AND EPIDEMIOLOGICAL MANIFESTATION OF HEPATOCELLULAR CARCINOMA IN PATIENTS BELONGING TO ETHNIC GROUPS OF CAUCASIANS AND ASIANS OF NORTH-EAST ASIA

39. CA209-9DX: Phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

42. gestion des sols et biodiversite

44. Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada

48. Factors associated with tumor recurrence after liver transplantation for hepatocellular carcinoma: prospective cohort on 371 patients

Catalog

Books, media, physical & digital resources